title: Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation.
abstract: OBJECTIVE
  Tumor recurrence after curative therapy is common for patients with hepatocellular carcinoma (HCC). As fibrosis and chronic inflammation contribute to the progression of HCC, we aimed to identify the predictive value of inflammatory and fibrosis markers for HCC recurrence after curative therapy using radiofrequency ablation (RFA).
  
  
  METHODS
  We retrospectively reviewed the records of patients with HCC treated with RFA between October 2005 and September 2013. The median duration of follow-up was 40 months (4-95 months). Inflammatory and fibrosis markers and demographic and clinical data were analyzed by Cox proportional hazards model using univariate and multivariate analyses and longitudinal analysis.
  
  
  RESULTS
  A total of 98 patients were included for analysis. There were 54 cases of HCC recurrence (55.1%). The aspartate aminotransferase-to-platelet ratio index (APRI; 2.3 ± 1.8 vs. 1.3 ± 1.4, P = 0.018) was significantly higher in the recurrence group than in the recurrence-free group. In multivariate analysis, APRI (hazard ratio, 2.64; confidence interval, 1.488-4.714; P = 0.001) was an independent risk factor for tumor recurrence. In particular, patients with APRI >1.38 showed a higher recurrence rate than patients with APRI ≤ 1.38 (P < 0.001). Longitudinal analysis showed persistently higher APRI values when assessed 12 months after RFA in patients who developed recurrence during follow-up than those who remained recurrence-free.
  
  
  CONCLUSIONS
  These findings show that a high APRI value is associated with HCC recurrence after RFA. Therefore, APRI could play an important role in predicting HCC recurrence after RFA.
authors.forename: Hyun Ah
authors.initials: HA
authors.lastname: Chung
authors.affiliation: Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Republic of Korea.
authors.forename: Jeong-Han
authors.initials: JH
authors.lastname: Kim
authors.forename: Young
authors.initials: Y
authors.lastname: Hwang
authors.forename: Hong Seok
authors.initials: HS
authors.lastname: Choi
authors.forename: Soon Young
authors.initials: SY
authors.lastname: Ko
authors.forename: Won Hyeok
authors.initials: WH
authors.lastname: Choe
authors.forename: So Young
authors.initials: SY
authors.lastname: Kwon
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D017115:Catheter Ablation / Q000379:methods*; D005260:Female; D006801:Humans; D008103:Liver Cirrhosis / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000378:metabolism* / Q000473:pathology; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor
references.citation: PLoS One. 2011;6(9):e25295
references.pmid: 21966488
references.citation: Hepatology. 2010 Aug;52(2):762-73
references.pmid: 20564355
references.citation: Eur J Radiol. 2005 Jun;54(3):400-7
references.pmid: 15899343
references.citation: J Gastroenterol Hepatol. 2015 Jan;30(1):131-8
references.pmid: 24995497
references.citation: Hepatol Int. 2010 Sep 24;4(4):691-9
references.pmid: 21286339
references.citation: Eur J Gastroenterol Hepatol. 2011 Jun;23(6):528-36
references.pmid: 21537128
references.citation: Gastroenterology. 2014 Jul;147(1):152-61
references.pmid: 24583062
references.citation: Hepatology. 2003 Aug;38(2):518-26
references.pmid: 12883497
references.citation: AJR Am J Roentgenol. 2011 Oct;197(4):789-94
references.pmid: 21940565
references.citation: Intern Med. 2008;47(7):569-75
references.pmid: 18379139
references.citation: J Hepatol. 2003 Feb;38(2):200-7
references.pmid: 12547409
references.citation: Gut. 2011 Aug;60(8):1109-16
references.pmid: 21270118
references.citation: Am J Gastroenterol. 2006 Jul;101(7):1500-8
references.pmid: 16863553
references.citation: J Gastroenterol Hepatol. 2011 Nov;26(11):1638-45
references.pmid: 22011297
references.citation: Can J Gastroenterol. 2000 Nov;14 Suppl D:60D-66D
references.pmid: 11110614
references.citation: Hepatogastroenterology. 2011 Jan-Feb;58(105):147-52
references.pmid: 21510303
references.citation: J Hepatol. 2012 Jan;56(1):55-62
references.pmid: 21781944
references.citation: Eur J Gastroenterol Hepatol. 2006 Apr;18(4):389-96
references.pmid: 16538110
references.citation: Cancer. 2000 Aug 1;89(3):500-7
references.pmid: 10931448
references.citation: Am J Gastroenterol. 2012 Feb;107(2):253-61
references.pmid: 22008893
references.citation: Gastroenterology. 2014 Jul;147(1):24-6
references.pmid: 24877866
references.citation: Clin Chim Acta. 2012 Nov 12;413(21-22):1725-30
references.pmid: 22759976
references.citation: J Am Coll Surg. 2008 Jul;207(1):20-9
references.pmid: 18589357
references.citation: Hepatol Int. 2008 Sep;2(3):263-83
references.pmid: 19669255
references.citation: Jpn J Clin Oncol. 2007 Sep;37(9):658-72
references.pmid: 17766723
references.citation: N Engl J Med. 2011 Sep 22;365(12):1118-27
references.pmid: 21992124
references.citation: Hepatol Res. 2002 Dec;24(4):395-403
references.pmid: 12479938
references.citation: Ann Surg. 2011 Mar;253(3):453-69
references.pmid: 21263310
references.citation: Eur J Radiol. 2006 Sep;59(3):432-41
references.pmid: 16690240
references.citation: J Gastroenterol Hepatol. 2008 Mar;23(3):453-8
references.pmid: 17725599